{"DataElement":{"publicId":"2212214","version":"1","preferredName":"Prior Agent Colorectal Cancer Therapy Type","preferredDefinition":"the type of prior agent used in colorectal cancer therapy.","longName":"PRIOR_AGT_CRC_TX_TP","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2212212","version":"1","preferredName":"Prior Agent Colorectal Cancer Therapy","preferredDefinition":"information relating to prior agent colorectal cancer therapy.","longName":"PRI_AGT_COLRCTLCA_TX","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2212209","version":"1","preferredName":"Prior Agent","preferredDefinition":"Earlier in time or order.:An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect. (NCI)","longName":"C25629:C1708","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Prior","conceptCode":"C25629","definition":"Earlier in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Agent","conceptCode":"C1708","definition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F428C665-74F0-2F56-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-04-07","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-04-07","modifiedBy":"ONEDATA","dateModified":"2005-04-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2212210","version":"1","preferredName":"Colorectal Cancer Therapy","preferredDefinition":"No value exists.:An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","longName":"C0009402:C15368","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Colorectal Cancer","conceptCode":"C0009402","definition":"No value exists.","evsSource":"UMLS_CUI","primaryIndicator":"No","displayOrder":"1"},{"longName":"Therapy","conceptCode":"C15368","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F428C665-74F5-2F56-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-04-07","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-04-07","modifiedBy":"ONEDATA","dateModified":"2005-04-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F428C665-74F7-2F56-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-04-07","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-04-07","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2212213","version":"1","preferredName":"Prior Agent Colorectal Cancer Therapy Type","preferredDefinition":"the type of prior agent used in colorectal cancer therapy.","longName":"PRIOR_AGT_CRC_TX_TP","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"35","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"5FU based therapy","valueDescription":"5FU based therapy","ValueMeaning":{"publicId":"2574347","version":"1","preferredName":"5FU based therapy","longName":"2574347","preferredDefinition":"5FU based therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EF78-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-04-07","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-04-07","modifiedBy":"SHIDED","dateModified":"2005-04-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F42E4FCA-F24C-24A2-E034-0003BA3F9857","beginDate":"2005-04-07","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-04-07","modifiedBy":"ONEDATA","dateModified":"2005-04-07","deletedIndicator":"No"},{"value":"Irinotecan","valueDescription":"Irinotecan","ValueMeaning":{"publicId":"2574348","version":"1","preferredName":"Irinotecan","longName":"2574348","preferredDefinition":"A semisynthetic derivative of camptothecin, a cytotoxic, quinoline-based alkaloid extracted from the Asian tree Camptotheca acuminata.  Irinotecan, a prodrug, is converted to a biologically active metabolite 7-ethyl-10-hydroxy-camptothecin (SN-38) by a carboxylesterase-converting enzyme.  One thousand-fold more potent than its parent compound irinotecan, SN-38 inhibits topoisomerase I activity by stabilizing the cleavable complex between topoisomerase I and DNA, resulting in DNA breaks that inhibit DNA replication and trigger apoptotic cell death.  Because ongoing DNA synthesis is necessary for irinotecan to exert its cytotoxic effects, it is classified as an S-phase-specific agent.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Irinotecan","conceptCode":"C62040","definition":"A semisynthetic derivative of camptothecin, a cytotoxic, quinoline-based alkaloid extracted from the Asian tree Camptotheca acuminata.  Irinotecan, a prodrug, is converted to a biologically active metabolite 7-ethyl-10-hydroxy-camptothecin (SN-38) by a carboxylesterase-converting enzyme.  One thousand-fold more potent than its parent compound irinotecan, SN-38 inhibits topoisomerase I activity by stabilizing the cleavable complex between topoisomerase I and DNA, resulting in DNA breaks that inhibit DNA replication and trigger apoptotic cell death.  Because ongoing DNA synthesis is necessary for irinotecan to exert its cytotoxic effects, it is classified as an S-phase-specific agent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EF79-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-04-07","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-04-07","modifiedBy":"HARTLEYG","dateModified":"2017-11-16","changeDescription":"Added concept code_11.16.17_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F42E4FCA-F250-24A2-E034-0003BA3F9857","beginDate":"2005-04-07","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-04-07","modifiedBy":"ONEDATA","dateModified":"2005-04-07","deletedIndicator":"No"},{"value":"Oxaliplatin","valueDescription":"Oxaliplatin","ValueMeaning":{"publicId":"2579327","version":"1","preferredName":"Oxaliplatin","longName":"2579327","preferredDefinition":"An organoplatinum complex in which the platinum atom is complexed with 1,2-diaminocyclohexane (DACH) and with an oxalate ligand as a 'leaving group.' A 'leaving group' is an atom or a group of atoms that is displaced as a stable species taking with it the bonding electrons. After displacement of the labile oxalate ligand leaving group, active oxaliplatin derivatives, such as monoaquo and diaquo DACH platinum, alkylate macromolecules, forming both inter- and intra-strand platinum-DNA crosslinks, which result in inhibition of DNA replication and transcription and cell-cycle nonspecific cytotoxicity. The DACH side chain appears to inhibit alkylating-agent resistance. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oxaliplatin","conceptCode":"C1181","definition":"An organoplatinum complex in which the platinum atom is complexed with 1,2-diaminocyclohexane (DACH) and with an oxalate ligand as a 'leaving group.' A 'leaving group' is an atom or a group of atoms that is displaced as a stable species taking with it the bonding electrons. After displacement of the labile oxalate ligand leaving group, active oxaliplatin derivatives, such as monoaquo and diaquo DACH platinum, alkylate macromolecules, forming both inter- and intra-strand platinum-DNA crosslinks, which result in inhibition of DNA replication and transcription and cell-cycle nonspecific cytotoxicity. The DACH side chain appears to inhibit alkylating-agent resistance. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-02EC-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-04-02","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-04-02","modifiedBy":"REEVESD","dateModified":"2006-05-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F42E4FCA-F253-24A2-E034-0003BA3F9857","beginDate":"2005-04-07","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-04-07","modifiedBy":"ONEDATA","dateModified":"2005-04-07","deletedIndicator":"No"},{"value":"Cetuximab","valueDescription":"Cetuximab","ValueMeaning":{"publicId":"2574309","version":"1","preferredName":"Cetuximab","longName":"2574309","preferredDefinition":"A monoclonal antibody specific for the epidermal growth factor receptor (EGFR), a tyrosine kinase that triggers cell division.  Cetuximab binds to and inhibits EGFRs, which are overexpressed on the cell surfaces of many types of tumors.  This agent blocks the tumor growth, invasion, and metastasis associated with the overexpression of cell-surface EGFRs. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cetuximab","conceptCode":"C1723","definition":"A recombinant, chimeric monoclonal antibody directed against the epidermal growth factor (EGFR) with antineoplastic activity. Cetuximab binds to the extracellular domain of the EGFR, thereby preventing the activation and subsequent dimerization of the receptor; the decrease in receptor activation and dimerization may result in an inhibition in signal transduction and anti-proliferative effects. This agent may inhibit EGFR-dependent primary tumor growth and metastasis. EGFR is overexpressed on the cell surfaces of various solid tumors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EF52-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-04-02","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-04-02","modifiedBy":"REEVESD","dateModified":"2006-05-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F42E4FCA-F255-24A2-E034-0003BA3F9857","beginDate":"2005-04-07","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-04-07","modifiedBy":"ONEDATA","dateModified":"2005-04-07","deletedIndicator":"No"},{"value":"Bevacizumab","valueDescription":"Bevacizumab","ValueMeaning":{"publicId":"2574306","version":"1","preferredName":"Bevacizumab","longName":"2574306","preferredDefinition":"A monoclonal antibody that may prevent the growth of blood vessels from surrounding tissue to a solid tumor.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bevacizumab","conceptCode":"C2039","definition":"A recombinant humanized monoclonal antibody directed against the vascular endothelial growth factor (VEGF), a pro-angiogenic cytokine.  Bevacizumab binds to VEGF and inhibits VEGF receptor binding, thereby preventing the growth and maintenance of tumor blood vessels.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EF4F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-04-02","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-04-02","modifiedBy":"ALAIS","dateModified":"2006-04-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F42E4FCA-F257-24A2-E034-0003BA3F9857","beginDate":"2005-04-07","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-04-07","modifiedBy":"ONEDATA","dateModified":"2005-04-07","deletedIndicator":"No"},{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"2567790","version":"1","preferredName":"Other","longName":"2567790","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D5DB-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-31","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-12-31","modifiedBy":"KUMMEROA","dateModified":"2023-11-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F42D2196-1C3B-05B0-E034-0003BA3F9857","beginDate":"2005-04-07","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-04-07","modifiedBy":"ONEDATA","dateModified":"2005-04-07","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2177853","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"Type","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C16D625D-02B6-1907-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-07-09","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-07-09","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CALGB CRF:Cancer and Leukemia Group B Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F42E4FCA-F224-24A2-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-04-07","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-04-07","modifiedBy":"SBR","dateModified":"2008-12-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008587","version":"2","longName":"Type of Disease","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811835","version":"1","longName":"Melanoma","context":"CTEP"},{"publicId":"2811871","version":"1","longName":"Colorectal","context":"CTEP"},{"publicId":"2811831","version":"1","longName":"Breast","context":"CTEP"},{"publicId":"2811908","version":"1","longName":"Gynecologic","context":"CTEP"},{"publicId":"2811909","version":"1","longName":"Leukemia","context":"CTEP"},{"publicId":"2811950","version":"1","longName":"Multiple Myeloma","context":"CTEP"}]},{"publicId":"2008589","version":"2","longName":"Type of Category","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811963","version":"1","longName":"Treatment","context":"CTEP"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"specify agents","type":"Preferred Question Text","description":"specify agents","url":null,"context":"CTEP"}],"origin":"CALGB CRF:Cancer and Leukemia Group B Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"F42E5180-EACD-1BFD-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-04-07","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-04-07","modifiedBy":"CAMPBELB","dateModified":"2008-07-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}